Literature DB >> 10781212

Systemic treatment of venous leg ulcers with high doses of pentoxifylline: efficacy in a randomized, placebo-controlled trial.

V Falanga1, R M Fujitani, C Diaz, G Hunter, J Jorizzo, P F Lawrence, B Y Lee, J O Menzoian, L L Tretbar, G A Holloway, J Hoballah, G R Seabrook, D E McMillan, W Wolf.   

Abstract

Several small studies have indicated that the systemic administration of pentoxifylline may accelerate healing of venous leg ulcers. The goal of this study was to further evaluate these findings in a larger scale placebo controlled trial and to explore the effect of the dose of pentoxifylline on healing. The study used a prospective, randomized, double-blind, parallel group placebo controlled design in a multicenter outpatient setting. Patients with one or more venous ulcer were enrolled, with all patients receiving standardized compression bandaging for treatment for their ulcers. Patients were also randomized to receive either pentoxifylline 400 mg, pentoxifylline 800 mg (two 400 mg tablets), or placebo tablets three times a day for up to 24 weeks. The main outcome measure was time to complete healing of all leg ulcers, using life table analysis. The study was completed as planned in 131 patients. Patients receiving 800 mg three times a day of pentoxifylline healed faster than placebo (p = 0.043, Wilcoxon test). The median time to complete healing was 100, 83, and 71 days for placebo, pentoxifylline 400 mg, and pentoxifylline 800 mg three times a day, respectively. Over half of all patients were ulcer free at week 16 (placebo) and at week 12 in both pentoxifylline groups. Whereas the placebo group had only achieved complete healing in half of the cases by week 16, all of the subjects remaining in the group receiving the high dose of pentoxifylline had healed completely. Treatment with pentoxifylline was well tolerated with similar drop-out rates in all three treatment groups. Complete wound closure occurred at least 4 weeks earlier in the majority of patients treated with pentoxifylline by comparison to placebo. A higher dose of pentoxifylline (800 mg three times a day) was more effective than the lower dose. We conclude that pentoxifylline is effective in accelerating healing of leg ulcers.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10781212     DOI: 10.1046/j.1524-475x.1999.00208.x

Source DB:  PubMed          Journal:  Wound Repair Regen        ISSN: 1067-1927            Impact factor:   3.617


  17 in total

Review 1.  Micronised purified flavonoid fraction: a review of its use in chronic venous insufficiency, venous ulcers and haemorrhoids.

Authors:  Katherine A Lyseng-Williamson; Caroline M Perry
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 2.  Matrix metalloproteinases as potential targets in the venous dilation associated with varicose veins.

Authors:  Arda Kucukguven; Raouf A Khalil
Journal:  Curr Drug Targets       Date:  2013-03       Impact factor: 3.465

Review 3.  Mesenchymal Stem Cells in Chronic Wounds: The Spectrum from Basic to Advanced Therapy.

Authors:  Marta Otero-Viñas; Vincent Falanga
Journal:  Adv Wound Care (New Rochelle)       Date:  2016-04-01       Impact factor: 4.730

Review 4.  Pentoxifylline for treating venous leg ulcers.

Authors:  Andrew B Jull; Bruce Arroll; Varsha Parag; Jill Waters
Journal:  Cochrane Database Syst Rev       Date:  2012-12-12

5.  Treatment of Venous Ulcers.

Authors:  Tami S De Araujo; Camile Luiza Hexsel; Robert S Kirsner
Journal:  Curr Treat Options Cardiovasc Med       Date:  2005-06

6.  Effective use of negative pressure wound therapy provides quick wound-bed preparation and complete graft take in the management of chronic venous ulcers.

Authors:  Onur Egemen; Ozay Ozkaya; Muhammed Besir Ozturk; Tolga Aksan; Çağdaş Orman; Mithat Akan
Journal:  Int Wound J       Date:  2011-10-12       Impact factor: 3.315

7.  Phase I study of H5.020CMV.PDGF-beta to treat venous leg ulcer disease.

Authors:  David J Margolis; Lee M Morris; Maryte Papadopoulos; Linda Weinberg; Jennifer C Filip; Stephanie A Lang; Sachin S Vaikunth; Timothy M Crombleholme
Journal:  Mol Ther       Date:  2009-07-28       Impact factor: 11.454

Review 8.  Neutrophil activity in chronic venous leg ulcers--a target for therapy?

Authors:  Jodi C McDaniel; Sashwati Roy; Traci A Wilgus
Journal:  Wound Repair Regen       Date:  2013-03-28       Impact factor: 3.617

9.  A prospective, multicentre, randomised controlled study of human fibroblast-derived dermal substitute (Dermagraft) in patients with venous leg ulcers.

Authors:  Keith Harding; Michael Sumner; Matthew Cardinal
Journal:  Int Wound J       Date:  2013-04       Impact factor: 3.315

10.  Comprehensive decision-analytic model and Bayesian value-of-information analysis: pentoxifylline in the treatment of chronic venous leg ulcers.

Authors:  Cynthia P Iglesias; Karl Claxton
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.